In this interview with David Horn Solomon, CEO of Silence Therapeutics, he discusses today’s announcement of a licensing and collaboration agreement with Mallinckrodt Pharmaceuticals to develop and commercialise RNAi drugs.
18 Jul 2019
Silence Therapeutics - Executive Interview
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Silence Therapeutics - Executive Interview
In this interview with David Horn Solomon, CEO of Silence Therapeutics, he discusses today’s announcement of a licensing and collaboration agreement with Mallinckrodt Pharmaceuticals to develop and commercialise RNAi drugs.